Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Sep 14;3(2):e000496. doi: 10.1136/rmdopen-2017-000496

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

PMC Copyright notice

Proportion of patients reporting improvement ≥MCID at 24 weeks in the (A) AMBITION and (B) ADACTA trial populations. Analyses were performed using the per-protocol population in the AMBITION (TCZ, n=265; MTX, n=259) and the intention-to-treat population in ADACTA (TCZ, n=163; ADA, n=162) and adjusted for site (AMBITION)/region (ADACTA), baseline score (ADACTA) and duration of RA. The MCID for PROs were defined as follows: HAQ-DI: ≥0.22; PtGA: ≥10; patient pain: ≥10; FACIT-Fatigue: ≥4; SF-36 PCS/MCS: ≥2.5; SF-36 domains: ≥5.0. ADA, adalimumab; BP, bodily pain; FACIT, Functional Assessment of Chronic Illness Therapy; GH, general health; HAQ-DI, Health Assessment Questionnaire Disability Index; MCS, mental component summary; MCID, minimum clinically important differences; MH, mental health; MTX, methotrexate; PCS, physical component summary; PF, physical functioning; PROs, patient-reported outcomes; PtGA, patient global assessment; RE, role-emotional; RP, role-physical; SF, social functioning; SF-36, Short Form-36; TCZ, tocilizumab; VT, vitality. *p<0.05; **p<0.01.